538 related articles for article (PubMed ID: 17532963)
1. Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study.
Tardif JC; Carrier M; Kandzari DE; Emery R; Cote R; Heinonen T; Zettler M; Hasselblad V; Guertin MC; Harrington RA;
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1604-11. PubMed ID: 17532963
[TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, multicenter study to evaluate the cardioprotective effects of MC-1 in patients undergoing high-risk coronary artery bypass graft surgery: MC-1 to Eliminate Necrosis and Damage in Coronary Artery Bypass Graft Surgery Trial (MEND-CABG) II--study design and rationale.
Mehta RH; Alexander JH; Emery R; Ellis SJ; Hasselblad V; Khalil A; Carrier M; Harrington RA; Tardif JC;
Am Heart J; 2008 Apr; 155(4):600-8. PubMed ID: 18371465
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of pyridoxal 5'-phosphate (MC-1) in high-risk patients undergoing coronary artery bypass graft surgery: the MEND-CABG II randomized clinical trial.
; Alexander JH; Emery RW; Carrier M; Ellis SJ; Mehta RH; Hasselblad V; Menasche P; Khalil A; Cote R; Bennett-Guerrero E; Mack MJ; Schuler G; Harrington RA; Tardif JC
JAMA; 2008 Apr; 299(15):1777-87. PubMed ID: 18381567
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of complement activation by pexelizumab reduces death in patients undergoing combined aortic valve replacement and coronary artery bypass surgery.
Carrier M; Ménasché P; Levy JH; Newman MF; Taylor KM; Haverich A; Chen JC; Shernan SK; Van de Werf F; van der Laan M; Todaro TG; Adams PX; Verrier ED
J Thorac Cardiovasc Surg; 2006 Feb; 131(2):352-6. PubMed ID: 16434264
[TBL] [Abstract][Full Text] [Related]
5. Protective effect of pyridoxal-5-phosphate (MC-1) on perioperative myocardial infarction is independent of aortic cross clamp time: results from the MEND-CABG trial.
Carrier M; Emery R; Kandzari DE; Harrington R; Guertin MC; Tardif JC
J Cardiovasc Surg (Torino); 2008 Apr; 49(2):249-53. PubMed ID: 18431346
[TBL] [Abstract][Full Text] [Related]
6. Effect of pexelizumab in coronary artery bypass graft surgery with extended aortic cross-clamp time.
Smith PK; Carrier M; Chen JC; Haverich A; Levy JH; Menasché P; Shernan SK; Van de Werf F; Adams PX; Todaro TG; Verrier E
Ann Thorac Surg; 2006 Sep; 82(3):781-8; discussion 788-9. PubMed ID: 16928483
[TBL] [Abstract][Full Text] [Related]
7. Translational research: is there a future?
Verrier ED
J Thorac Cardiovasc Surg; 2007 Jun; 133(6):1409-11. PubMed ID: 17532929
[No Abstract] [Full Text] [Related]
8. Impact of pexelizumab, an anti-C5 complement antibody, on total mortality and adverse cardiovascular outcomes in cardiac surgical patients undergoing cardiopulmonary bypass.
Shernan SK; Fitch JC; Nussmeier NA; Chen JC; Rollins SA; Mojcik CF; Malloy KJ; Todaro TG; Filloon T; Boyce SW; Gangahar DM; Goldberg M; Saidman LJ; Mangano DT;
Ann Thorac Surg; 2004 Mar; 77(3):942-9; discussion 949-50. PubMed ID: 14992903
[TBL] [Abstract][Full Text] [Related]
9. Pexelizumab reduces death and myocardial infarction in higher risk cardiac surgical patients.
Haverich A; Shernan SK; Levy JH; Chen JC; Carrier M; Taylor KM; Van de Werf F; Newman MF; Adams PX; Todaro TG; van der Laan M; Verrier ED
Ann Thorac Surg; 2006 Aug; 82(2):486-92. PubMed ID: 16863750
[TBL] [Abstract][Full Text] [Related]
10. Increased creatine kinase MB level predicts postoperative mortality after cardiac surgery independent of new Q waves.
Ramsay J; Shernan S; Fitch J; Finnegan P; Todaro T; Filloon T; Nussmeier NA
J Thorac Cardiovasc Surg; 2005 Feb; 129(2):300-6. PubMed ID: 15678039
[TBL] [Abstract][Full Text] [Related]
11. Preoperative statin therapy is associated with reduced cardiac mortality after coronary artery bypass graft surgery.
Collard CD; Body SC; Shernan SK; Wang S; Mangano DT; ;
J Thorac Cardiovasc Surg; 2006 Aug; 132(2):392-400. PubMed ID: 16872968
[TBL] [Abstract][Full Text] [Related]
12. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial.
El-Hamamsy I; Stevens LM; Carrier M; Pellerin M; Bouchard D; Demers P; Cartier R; Page P; Perrault LP
J Thorac Cardiovasc Surg; 2007 Jan; 133(1):7-12. PubMed ID: 17198774
[TBL] [Abstract][Full Text] [Related]
13. Biochemical assessment of myocardial injury after cardiac surgery: effects of a platelet activating factor antagonist, bilateral internal thoracic artery grafts, and coronary endarterectomy.
Taggart DP
J Thorac Cardiovasc Surg; 2000 Oct; 120(4):651-9. PubMed ID: 11003744
[TBL] [Abstract][Full Text] [Related]
14. Effects of angiotensin-converting enzyme inhibition in low-risk patients early after coronary artery bypass surgery.
Rouleau JL; Warnica WJ; Baillot R; Block PJ; Chocron S; Johnstone D; Myers MG; Calciu CD; Dalle-Ave S; Martineau P; Mormont C; van Gilst WH;
Circulation; 2008 Jan; 117(1):24-31. PubMed ID: 18071079
[TBL] [Abstract][Full Text] [Related]
15. The association of elevated creatine kinase-myocardial band on mortality after coronary artery bypass grafting surgery is time and magnitude limited.
Engoren MC; Habib RH; Zacharias A; Schwann TA; Riordan CJ; Durham SJ; Shah A
Eur J Cardiothorac Surg; 2005 Jul; 28(1):114-9. PubMed ID: 15982595
[TBL] [Abstract][Full Text] [Related]
16. Randomized trial of atorvastatin for reduction of myocardial damage during coronary intervention: results from the ARMYDA (Atorvastatin for Reduction of MYocardial Damage during Angioplasty) study.
Pasceri V; Patti G; Nusca A; Pristipino C; Richichi G; Di Sciascio G;
Circulation; 2004 Aug; 110(6):674-8. PubMed ID: 15277322
[TBL] [Abstract][Full Text] [Related]
17. Myocardial injury in coronary artery bypass grafting: on-pump versus off-pump comparison by measuring high-sensitivity C-reactive protein, cardiac troponin I, heart-type fatty acid-binding protein, creatine kinase-MB, and myoglobin release.
Chowdhury UK; Malik V; Yadav R; Seth S; Ramakrishnan L; Kalaivani M; Reddy SM; Subramaniam GK; Govindappa R; Kakani M
J Thorac Cardiovasc Surg; 2008 May; 135(5):1110-9, 1119.e1-10. PubMed ID: 18455592
[TBL] [Abstract][Full Text] [Related]
18. Treatment with clarithromycin prior to coronary artery bypass graft surgery does not prevent subsequent cardiac events.
Berg HF; Maraha B; Scheffer GJ; Quarles-van Ufford M; Vandenbroucke-Grauls CM; Peeters MF; Kluytmans JA
Clin Infect Dis; 2005 Feb; 40(3):358-65. PubMed ID: 15668857
[TBL] [Abstract][Full Text] [Related]
19. Emergency coronary artery bypass graft surgery for acute coronary syndrome: beating heart versus conventional cardioplegic cardiac arrest strategies.
Rastan AJ; Eckenstein JI; Hentschel B; Funkat AK; Gummert JF; Doll N; Walther T; Falk V; Mohr FW
Circulation; 2006 Jul; 114(1 Suppl):I477-85. PubMed ID: 16820622
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN).
Knopp RH; d'Emden M; Smilde JG; Pocock SJ
Diabetes Care; 2006 Jul; 29(7):1478-85. PubMed ID: 16801565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
